Heghine Khachatryan: How Well Do We Recognize Anti-PF4 Disorders?
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared Shinya Goto‘s post on LinkedIn:
“An outstanding and highly relevant review on platelet-activating anti-PF4 disorders.
For practicing clinicians, these immune-mediated thrombotic syndromes are no longer rare academic entities.
HIT, autoimmune HIT, spontaneous HIT, VITT, and VITT-like disorders are increasingly recognized across diverse clinical settings, making early suspicion, timely laboratory diagnosis, and prompt initiation of appropriate therapy essential for improving patient outcomes.
This review provides an excellent synthesis of current concepts in the pathophysiology, diagnosis, and management of anti-PF4 disorders and will undoubtedly become an important reference for physicians involved in thrombosis, hemostasis, intensive care, hematology, and vascular medicine.
Congratulations to the authors on this outstanding contribution to the field.”
Shinya Goto, Director and Chairman in Metabolic Disease Research Center, shared a post on LinkedIn about a recent article by Theodore E. Warkentin et al., published in NEJM, adding:
“Very good review regarding Platelet-Activating Anti–Platelet Factor 4 Disorders including HIT!”
Title: Very good review regarding Platelet-Activating Anti–Platelet Factor 4 Disorders including HIT!
Authors: Theodore E. Warkentin, Andreas Greinacher
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Aug 16, 2026, 12:16Jeff Schaffnit: The Power of Community in Rare Blood Disorders
-
Aug 16, 2026, 12:03Fawaz AlOtaibi: Can AI Replace Contrast CTA for Vascular Screening?
-
Aug 16, 2026, 10:31Erhabor Osaro: Critical Issues to Consider During the Clinical Blood Transfusion Process
-
Aug 16, 2026, 10:14Juan Manuel Cisneros Carrasco: The Architects Behind the Blood Donation System
-
Aug 16, 2026, 10:06Honoring the Life and Legacy of Dr. Reed Pyeritz – GADA Canada
-
Aug 16, 2026, 09:51Javier Amador-Castañeda: When a 32 Percent Reduction Tells Only Part of the Story
-
Aug 16, 2026, 09:33Anıl Güneş: The Unseen Threat – How Global Climate Change Impacts Cardiovascular Health
-
Aug 16, 2026, 09:09Robert John Nesbitt: Can We Prevent Stroke Without Increasing Bleeding Risk
-
Aug 16, 2026, 06:19Dennis Wolf: Is ZEUS the End of Anti-Inflammatory Therapy in Atherosclerosis?